CD274 and cancer: Aptamers that bind to surface proteins such as PD‐L1 (programmed death‐ligand 1)93 or PD‐1 (programmed death‐1),94 can be conjugated to nanoparticles for targeted delivery to cancer or immune cells, such as T lymphocytes, B, and natural killer (NK) cells involved in cancer immunotherapy.